ALY-301 is a first-in-class bispecific antibody targeting c-Kit and CD-203c with mast cell selectivity Designed to enable safe dosing in chronic conditions and deliver clinical proof-of concept ...

Understanding how molecules interact is central to biology: from decoding how living organisms function to uncovering disease ...

Merck (MRK) on Monday announced positive results from the first two of three late-stage clinical trials evaluating the safety ...

WILMINGTON, DE — Incyte (Nasdaq: INCY) is set to present pivotal data from its hematology/oncology portfolio at the 2025 ...

The novel selective antibody sibeprenlimab reduced proteinuria more than any prior drug for IgA nephropathy, with excellent ...

In the Phase III VISIONARY study, sibeprenlimab, an investigational monoclonal antibody, showed a 51.2% reduction in ...

Heidelberg Pharma invites individual and institutional investors, as well as advisors and analysts, to attend online at ...

Sanofi's $470M Vigil Neuroscience, Inc. acquisition highlights VG-3927's potential in Alzheimer's. Click here to find out why ...

Rakuten Medical, Inc., a global biotechnology company developing and commercializing Alluminox™ platform-based photoimmunotherapy, today announced that its third drug candidate, RM-0256, has been ...

As CIDP moves toward targeted therapies and patient-friendly regimens, the market is primed for disruption—offering a fresh ...

Learn how antibody to payload design is crucial for advancing ADC technology in oncology and beyond with expert insights.

Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing ...